Salud financiera de hoja de balance de Y-mAbs Therapeutics

Salud financiera controles de criterios 6/6

Y-mAbs Therapeutics tiene unos fondos propios totales de $100.2M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $128.9M y $28.7M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$78.64m
Patrimonio	US$100.99m
Total pasivo	US$26.88m
Activos totales	US$127.87m

Actualizaciones recientes sobre salud financiera

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12

Recent updates

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Jan 14

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Nov 13

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Jul 16

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12

Y-mAbs Therapeutics (NASDAQ:YMAB) Is In A Good Position To Deliver On Growth Plans

Dec 09

Análisis de la situación financiera

Pasivos a corto plazo: YMABLos activos a corto plazo ($114.9M) de la empresa superan a sus pasivos a corto plazo ($21.8M).

Pasivo a largo plazo: YMABLos activos a corto plazo ($114.9M) superan a sus pasivos a largo plazo ($6.9M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: YMAB está libre de deudas.

Reducción de la deuda: YMAB no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: YMAB tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: YMAB dispone de suficiente liquidez para 2.7 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 12.2% cada año.

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Y-mAbs Therapeutics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

Recent updates

Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024

Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Consensus estimates of losses per share improve by 42%

Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Y-mAbs Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Price target increased by 9.3% to US$13.67

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Founder exercised options to buy US$370k worth of stock.

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$795k worth of stock

Founder notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Y-mAbs Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Y-mAbs Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective from November 6, 2023

Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma

Consensus EPS estimates upgraded to US$0.70 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Y-mAbs Therapeutics, Inc. Announces DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil

Consensus revenue estimates increase by 27%

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Price target increased by 11% to US$10.50

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Updates Financial Guidance for the Full-Year 2023

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Consensus estimates of losses per share improve by 14%

Price target decreased by 15% to US$9.14

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Y-mAbs Therapeutics, Inc. and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

Rosen Law Firm Encourages Y-Mabs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB

Price target decreased to US$10.88

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Y-mAbs Therapeutics, Inc. Announces National Medical Products Administration in China Has Granted Danyelza 40Mg/10Ml Conditional Approval

Y-mAbs Therapeutics, Inc. Announces Complete Response Letter for Omburtamab Biologics License Application

Price target decreased to US$12.00

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2022

Y-mAbs Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Consensus EPS estimates fall by 18%

Y-mAbs Therapeutics Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

Y-mAbs Therapeutics, Inc Announces Pivotal Data for Omburtamab

Y-Mabs Therapeutics, Inc. Announces Scheduling of Fda Advisory Committee Meeting for Omburtamab

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

Consensus EPS estimates fall by 16%

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Y-mAbs Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Y-mAbs Therapeutics, Inc. Announces Initiation of its First Clinical Trial with SADA Construct

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Y-mAbs Therapeutics, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for Omblastys (Omburtamab) for the Treatment of Neuroblastoma for Priority Review

Y-mAbs Therapeutics, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for Omblastys (Omburtamab) for the Treatment of Neuroblastoma for Priority Review

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

Y-mAbs Therapeutics, Inc Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

Consensus revenue estimates increase by 16%

Consensus EPS estimates fall by 19%

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

Y-mAbs Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022